Literature DB >> 25631596

Australian Rotavirus Surveillance Program annual report, 2013.

Carl D Kirkwood1, Susie Roczo-Farkas2.   

Abstract

This report from the Australian Rotavirus Surveillance Program, together with collaborating laboratories Australia-wide, describes the rotavirus genotypes responsible for the hospitalisation of children with acute gastroenteritis during the period 1 January to 31 December 2013. During the survey period, 1,035 faecal samples were referred for rotavirus G and P genotype analysis. Of these 828 were confirmed as rotavirus positive. A total of 503 specimens were collected from children under 5 years of age, while 325 were from older children and adults. Genotype analysis of the 828 rotavirus samples collected from both children and adults revealed that G12P[8] was the dominant genotype in this reporting period, identified in 33% of strains nationally. Genotype G3P[8] was the second most common strain nationally, representing 31% of samples, followed by genotype G2P[4] (14%). This represents the first report where G12P[8] strains are the major cause of disease in this population. The genotype distribution was slightly altered when the analysis was restricted to samples collected from children under 5 years of age, with G3P[8] being the dominant genotype (39.2%) followed by G12P[8] as the second most common genotype (31%). Fluctuations in genotype distribution were also observed based on the vaccine type in use. Genotype G12P[8] was more common in states and territories using RotaTeq, while G3P[8] was more common in the locations using Rotarix. This survey highlights the yearly fluctuations in rotavirus genotypes observed since vaccine introduction, with changes in dominant genotypes an annual event. The emergence of G12P[8] as the dominant genotype further illustrates the ongoing changes in the wild type rotavirus population evident in the Australian population since vaccine introduction. This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or by email to copyright@health.gov.au.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25631596

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  7 in total

1.  Development of a Real-Time Reverse Transcription-PCR Assay To Detect and Quantify Group A Rotavirus Equine-Like G3 Strains.

Authors:  Eric M Katz; Mathew D Esona; Rashi Gautam; Michael D Bowen
Journal:  J Clin Microbiol       Date:  2021-08-25       Impact factor: 5.948

2.  Reverse Genetics Approach for Developing Rotavirus Vaccine Candidates Carrying VP4 and VP7 Genes Cloned from Clinical Isolates of Human Rotavirus.

Authors:  Yuta Kanai; Misa Onishi; Takahiro Kawagishi; Pimfhun Pannacha; Jeffery A Nurdin; Ryotaro Nouda; Moeko Yamasaki; Tina Lusiany; Pattara Khamrin; Shoko Okitsu; Satoshi Hayakawa; Hirotaka Ebina; Hiroshi Ushijima; Takeshi Kobayashi
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

3.  Resurgence of Rotavirus Genotype G12 in St. Louis During the 2014-2015 Rotavirus Season.

Authors:  Kristine M Wylie; Katherine M Stanley; Erin McElvania TeKippe; Kusal Mihindukulasuriya; Gregory A Storch
Journal:  J Pediatric Infect Dis Soc       Date:  2017-11-24       Impact factor: 3.164

4.  Rotavirus Strain Trends During the Postlicensure Vaccine Era: United States, 2008-2013.

Authors:  Michael D Bowen; Slavica Mijatovic-Rustempasic; Mathew D Esona; Elizabeth N Teel; Rashi Gautam; Michele Sturgeon; Parvin H Azimi; Carol J Baker; David I Bernstein; Julie A Boom; James Chappell; Stephanie Donauer; Kathryn M Edwards; Janet A Englund; Natasha B Halasa; Christopher J Harrison; Samantha H Johnston; Eileen J Klein; Monica M McNeal; Mary E Moffatt; Marcia A Rench; Leila C Sahni; Rangaraj Selvarangan; Mary A Staat; Peter G Szilagyi; Geoffrey A Weinberg; Mary E Wikswo; Umesh D Parashar; Daniel C Payne
Journal:  J Infect Dis       Date:  2016-06-14       Impact factor: 5.226

5.  Did Large-Scale Vaccination Drive Changes in the Circulating Rotavirus Population in Belgium?

Authors:  Virginia E Pitzer; Joke Bilcke; Elisabeth Heylen; Forrest W Crawford; Michael Callens; Frank De Smet; Marc Van Ranst; Mark Zeller; Jelle Matthijnssens
Journal:  Sci Rep       Date:  2015-12-21       Impact factor: 4.379

6.  Rotavirus A in Brazil: Molecular Epidemiology and Surveillance during 2018-2019.

Authors:  Meylin Bautista Gutierrez; Alexandre Madi Fialho; Adriana Gonçalves Maranhão; Fábio Correia Malta; Juliana da Silva Ribeiro de Andrade; Rosane Maria Santos de Assis; Sérgio da Silva E Mouta; Marize Pereira Miagostovich; José Paulo Gagliardi Leite; Tulio Machado Fumian
Journal:  Pathogens       Date:  2020-06-27

Review 7.  Rotavirus Strain Trends in United States, 2009-2016: Results from the National Rotavirus Strain Surveillance System (NRSSS).

Authors:  Slavica Mijatovic-Rustempasic; Jose Jaimes; Charity Perkins; M Leanne Ward; Mathew D Esona; Rashi Gautam; Jamie Lewis; Michele Sturgeon; Junaid Panjwani; Gail A Bloom; Steve Miller; Erik Reisdorf; Ann Marie Riley; Morgan A Pence; James Dunn; Rangaraj Selvarangan; Robert C Jerris; Dona DeGroat; Umesh D Parashar; Margaret M Cortese; Michael D Bowen
Journal:  Viruses       Date:  2022-08-15       Impact factor: 5.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.